# XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

> **NCT02721459** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 26 (actual)

## Conditions studied

- Melanoma
- Skin Cancer

## Interventions

- **DRUG:** XL888
- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT02721459
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-07
- **Primary completion:** 2019-10-31
- **Final completion:** 2026-11-04
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02721459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02721459, "XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02721459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*